Note: Descriptions are shown in the official language in which they were submitted.
CA 02358498 2001-07-03
WO 00/40275 PCT/N099/00392
1
The preparation and use of radiunm-223 to target calcif5ed tissues for pain
palliation, bone cancer therapy, and bone surface conditioning
The present invention relates to the preparation and use of the "calcium
analogue"
alkaline-earth radionuclide radium-223 for the targeting of calcified tissues,
e.g., bone
and a physiological acceptable solution comprising 223 Ra.
Biomedical use of radionuclides for pain palliation and/or cancer treatment,
including
prophylactic treatment of bone surfaces to slow down/inactivate undetectable
metastases has previously been based upon B-emitters and conversion electron
emitters.
A substantial percentage of cancer patients is affected by skeletal
metastases. As
many as 85% of patients with advanced lung, prostate and breast carcinoma
develop
bony metastases (Garret, 1993; Nielsen et al., 1991). Established treatments
such as
hormone therapy, chemotherapy and external radiotherapy often causes temporary
responses, but ultimately most bone cancer patients experience relapses
(Kanis,
1995). There is thu a strong need for new therapies to relieve pain and slow
down
tumor progression. Bone targeting radioisotopes has been included in clinical
trials
for the treatment of cancer to the skeleton (De Klerk et al., 1992, Fossi et
al., 1992,
Lee et al., 1996, Silberstein, 1996). These radiopharmaceuticals have been
based on
p-particle emitters (Atkins, 1998) and lately also a conversion electron
ermitter
(Atkins et al., 1995).Among these compounds which have so far been approved by
US Food and Drug Administration, Le., Ugstrontium-89 (MetastronT"'') and 1S3Sm
EDTMP (Lexidronam17''). The strontium-89 compound can only be administered in
amounts sufficient for pain palliation, not for tumor therapy, because a
significant
myelotoxicity occurs before significant antitumour therapeutic dose levels can
be
reached (Silberman, 1996).
Recently, one of the inventors authored a publication (Larsen et al., 1999)
showing by
dosimetry that a-emitters can be more advantageous than R-emitters as bone
seekers.
I.e. the shorter range of the a-emitters effecting less bone marrow exposure
when the
source is located at bone surfaces. ln this study two a-emitting
bisphosphonate bone
seekers were compared with two a-emitting compounds with similar chemical
structures and bone affinity. Dosimetric calculations indicated that, in mice,
the bone
surface to bone marrow dose ratios were approximately 3 times higher with the
a-emitter compared to the (3-emitter. This indicates that a-emitting bone
seekers may
have advantages over R- and/or electron emitting compounds because the
radiation
dose can be more strongly concentrated to the bone surfaces. Because of the
short
half life (tjn = 7.2 h) and since its production is limited to only a few
sites worldwide,
astatine-211 is at present not yet available for large scale marketing.
CA 02358498 2001-07-03
WO 00/40295 PCT/N099/00392
2
Besides astatine-211 only a few a-particle emitting radioisotopes are at
present
considered useful for biomedical applications (Feinendegen et al., 1997). The
lead-212/bismuth-212 system has previously been used for preparation of bone
seeking agents. Bismuth-212 complexed with ethylene-diamine-tetra(methylene-
phosphonic acid) (EDTMP), or 1,4,7, 1 0-tetraazacyclododecane 1,4,7,10-
tetra(methylene-phosphonic acid) (DOTMP), showed a significant bone affinity.
But
because of the short half life of bismuth-212 (tin= 60.6 min), normal tissue
exposure
during the uptake phase of the radiopharmaeeutical would be considerable
(Hassfjell
et al., 1994, 1997). This would be ever more pronounced with the other a-
emitting
bismuth isotope considered for biomedical use, the bismuth-213 (t 1/2= 46
min).
Attempts have been made to use the (3-emitter lead-212 (t,R = 10.6 h) as an in
vivo
generator for 212Bi. However, a significant translocation affecting a high
kidney
accumulation of the a-emitter was observed (Hassfjell et al., 1997). Other a-
emitting
radioisotopes potentially useful for biomedical applications are the radium
isotopes
224 and 226. As with other group I 1 alkaline-earth metals, radium in its
cationic state
is a natural boneseeker.
Previously the radium isotopes 224 and 226 has been studied, partly because of
their
bone affinity (Loyd et al., 1982, 1991; Muggenburg et al., 1996, Mtlller,
1971;
Raabe et al., 1993; Rundo, 1978). Radium-226 is, because of its long half-life
(1600
years) and its noble gas radon-222 daughter (tln = 3.8 days), not considered
useful
for targeted radionuclide therapy. Because of its chemical nature, radon is
inert to
chemical bonding under in vivo conditions. It can therefore readily
translocate in vivo
when generated from the decay of the mother nuclide (Rundo, 1978). Inhaled
radon
mainly dissolves in body fluid and fat and is mainly eliminated from the body
by
exhalation (Rundo, 1978). In an experiment using bone samples, Lloyd and
Bruenger
(1991) reported that 89.5-94.25 % of the radon-222 escaped from the bone after
radium-226 had been administered to dogs. In contrast to radium-226, radium-
224
has a half life(tu2 -3.64 days) which seems very suitable for biomedical
applications.
224Ra. was used medically for many years to treat ankylosing spondylitis
(Delikan,
1978). Unfortunately, also a significant fraction of the daughter isotopes of
radium-224 escaped from bone, probably mainly because of the radon-220 (t1n of
55.6 s) daughter (Lloyd et al., 1982; Miiller et al., 1971; Rundo, 1978).
It is thus known from previous studies that when the radium isotopes 224Ra and
226Ra
were incorporated in bone, a significant translocalisation of their radon
daughters
occurred, which could, at least partly, explain the known carcinogenic effect
of these
two radium isotopes. This may be one of the reasons why a-emitters have not
been
evaluated clinically as bone seeking radiopharmaceutical against skeletal
cancers.
It is the object of the present invention to provide a bone seeking
radionuclide useful
as a pharmaceutical agent, showing that radioactive decay products from its
CA 02358498 2001-07-03
WO 00/40275 PCT/N099/00392
3
transformation do not translocalize significantly after its incorporation in
bone
(valid at least after 3 days from administration).
The present inventors made the significant and somewhat unexpected discovery
that
from "Ra localized in bone, very little translocation of the radon daughter
(as well as
other radionuclides from the decay chain) occurred. Hence, the 223Ra series
may be
used to irradiate the bone surface without any significant translocation of
radionuclides (including diffusion into bone marrow). Furthermore radium-223,
should be more suitable as a boneseeking radiopharmac utical since the half
life (11.4
days) is about three times that of 224Ra, allowing a deeper incorporation into
the
matrix of the bone surfaces before decay occurs. Also, perhaps even more
important,
the radon daughter radon-219 has a short half-life (3.9 seconds), which should
diminish translocation in, or as a result from the radon step. Three of the
four
a-particles emitted during decay of 223Ra and daughter nuclides are emitted
immediately following 2oRa transformation (Seelman-Eggebert et al., 1981),
i.e., of
the first three transformations following 223 Ra, the 3.9 second 219Rn alpha
decay is the
one with the longest half life (Table 1). The last a-emitter in the 223 Ra
chain, 21Bi
(tln = 2.15 min) follows the decay of the (3-emitter lead-211 (tin = 36.1 min)
and may
therefore show some tranalocation. However, if the precursor, lead-211, is
trapped
inside of the bone matrix, also the last a-particle in the 223Ra series may be
delivered
to the bone surface area. In addition a-particles are high linear energy
transfer
(high-LET) radiation that is extremely cytotoxic to mammalian cells (Hall,
1994;
Ritter et al., 1977). An a-particle emitting radiation source localized in
target tissue
can deliver radiation to a smaller target area, thus reducing normal tissue
exposure
compared to a-emitters.
The present invention relates to the preparation and the use of the "calcium
analogue"
alkaline-earth radionuclide radium-223 for the targeting of calcified tissues,
e.g., bone
and a physiological acceptable solution comprising 223 Ra.
In this patent application the inventors have invented a novel use of 223Ra,
i.e., as an
a-emitting radiopharmaceutical for targeting of calcified tissues, e.g., bone
surfaces
and osseous tumor lesions. As indicated by the properties of the
radionuclide(s) as
well as the experimental examples presented in the present patent application,
radium-223 can be suitable as a bone seeking radiopharmaceutical. As an
example, the
invention may be used for prophylactic cancer treatment by delivering a
focused dose
to bone surfaces in patients with a high probability of having undetected
micrometastases at bone surfaces. Another example of its potential use would
be in
the treatment of painful osseous sites in a similar fashion as the previously
described
R- and electron emitting radiopharmaceuticals for bone pain palliation.
Radium-223 localized onto the bone surfaces and/or in calcified tumors can,
together
with its daughter nuclides, deliver an intense and highly local dose of a-
particles with
CA 02358498 2001-07-03
WO 00/40275 PCT/N099/00392
4
less bone marrow dose compared to currently used (i-emitting and/or electron
emitting radiopharmaceuticals. Skeletal diseases, e.g., primary or metastatic
cancer to
the bone may be treated with the n3Ra radiopharmaceutical.
The present invention includes the use of the nuclide as a cationic species
and/or
associated to a chelator or another form of a carrier molecule with affinity
for
calcified tissues. This also includes, but are not limited to the combination
of
radium-223 with a chelator that can be subsequently conjugated to a molecule
with
affinity for calcified tissues. The intent is to use the radioisotope to
generate a
cascade of a-particles on bone surfaces and/or in calcified tumors for the
palliation of
pain caused by various diseases and/or for the prophylactic use against
possible
minimal disease to the skeleton, and/or also for the therapeutic treatment of
established cancer to the bone. The diseases where the radioisotopes could be
used
includes, but are not limited to skeletal metastases of prostate-, breast-,
kidney- and
lung cancer as well as primary bone cancer and also multiple myeloma.
Radium-223 solutions are prepared for use in the targeting of calcified
tissues or for
bone surface irradiation. The following examples are showing a high and
selective
uptake of the Z23Ra in bone with very little relocalization of daughter
nuclides. This
shows that bone surfaces can be sterilized to inactivate microscopical
deposits of
cancer cells and also that calcified cancerous lesions can be irradiated
either for
palliation or therapy with this isotope. The compound differs from other
commonly
used radiopharmaceuticals with bone affmity because the main dose component
comes
from a- particles which has a much shorter range compared to the frequently
used
beta and electron emitters. Therefore the dose delivered to red bone marrow
can be
significantly reduced with this new compound, i.e., myelotoxicity is likely to
be
reduced. Radium-223 differs from the previously used medical radionuclide
radium-224 in the following: (1) 223Ra has a significantly longer half-life
affecting
better bone to soft tissue ratios because a significantly larger fraction of
this isotope
would be eliminated from the soft tissues before decay occurs. (2) Longer half
life
also allows a deeper incorporat'ion of tha radionuclide into the bone surfaces
as the
bone synthesis progresses, potentially improving retention of daughter
isotopes which
may otherwise translocate because of chemical diffusion and nuclear recoil.
(3) Also
the shorter half life of the 219Rn from 223Ra compared to the 220Rn from
224Ra, ensures
less translocation of daughter nuclides from the 223Ra series.
The 223Ra salt or derivative thereof will be administered to a mammal, such as
a
human, in need thereof by all available administration routes, such as oral,
subcutaneous, intravenous, intraarterial or transcutane. Preferably the active
compound is administered by injection or infusion.
Oral administration is performed by use of tablets, capsules, powders or in
liquid
form, such as suspension, solution, syrup or emulsion. When formed into
tablets
CA 02358498 2001-07-03
wo'o0%40273. rcTnvo99/00392
conventional expicihnts, lubricating agents and binding agents are used. When
administered as liquids conventional liquid carriers are used. When
administered as
injection or inftisionsolutions the carrier is preferably isotonic saline,
with or without
agent(s) to stabilize-the radium cation to prevent precipitation of radium
salts or
5 insoluble complexes.
The active principle aceordirig to the invention could be used both in
prophylactic,
palliative and therapeutic treatment of non-malignant and malignant diseases
affecting
bones and soft tissues. The malignant diseases are selected from the group
consisting
of prostate cancer, breast cancer, kidney and urinary cancer, primary bone
cancer,
lung cancer and multiple myeloma, and the non-malignant disease are selected
from
the group consisting of autoimmune diseases affecting joints and skeleton,
e.g.
rheumatoid arthritis, schleroderma and spondyloartropathies.
The physiologically acceptable preparation for in vivo administration
according to the
present invention comprises dissolved radium-223 salt, with or without a
single or a
combination of several cations, as stabilizing alkaline earth metal cation
analogue
carrier, with or without an agent to prevent precipitation and/or generation
of
colloids, in addition to pharmacologically acceptable carriers and adjuvans.
The cation
acting as stabilizing alkaline earth metal cation can be selected from the
group
consisting of magnesium, calcium and strontium. Furthermore, the agent to
prevent
precipitation and/or generation of colloids is a carboxylic acid or a
combination of
carboxylic acids, such as oxalic acid, oxaloacetic acid, tartaric acid,
succinic acid,
malic acid and malonic acid. The concentrations of the compounds in the
preparation
will generally be less than the individual LD SO dose, for example less than
20% of
the LD 50 dose, and thus vary for the different components. The activity of
223Ra will
be dependent upon the type and route of administration and the underlying
condition
or disease and will vary between approximately 50 kBq to approximately 10 MBq,
administered in single or multiple doses for mammals, such as for example
humans.
According to the invention radium-223 is furthermore used to produce a
pharmaceutically active preparation to treat non-malignant and malignant
diseases
affecting bone, bone surfaces and soft tissues, both palliative and
therapeutically. The
preparation is administered to the mammal, such as humans or animals ,i.e.
dogs, in
need thereof, in a palliative or therapeutically effective amount.
According to the invention radium-223 can be used in a combination therapy,
wherein
the Z23Ra preparation is combined with the following classes of treatment;
chemotherapy including bisphosphonates, surgery, external beam irradiation,
low-
LET radiation emitting bone seeking radiopharmaceuticals, and hormonal
treatment.
The invention is furthermore directed to a kit including MRa produced
according to
the inventive method, cations as stabilizing alkaline earth metal cation
analogue
qCA 02358498 2001-07-03
WO 00/40275 PGT/N099/00392
6
carrier according and an agent to prevent precipitation and/or generation of
colloids
in addition to pharmaceutically acceptable carriers and suitable
administration
equipment.
In the following the present invention is described in detail by examples
which in no
way is intended to limit the scope of the invention as described by the
enclosed
claims.
Table 1 presents the physical properties of radium-223 and its daughter
nuclides "
(Ekstr6m et al., 1989). The decay of the 223Ra and its daughters causes the
emissions
of four a-particles. Such a cascade of a-particles can deliver a large
radiation dose to
a limited volume. Radium-223 therefore possesses extreme cytotoxicity, also
compared to most a-emitters (Howell et al, 1997).
The following shows the Radium-223 and its daughters decay series (half life
and
mode of decay in brackets):
223Ra (11.4 d., a) => 219Rn (3.9 s., a) 215Po (1.8 ms., a) :~* 21'Pb
(36,1 min.,(3') =:> Z"Bi (2.15 ntin., a) ~ 207T1(4,8 min., ~l =:>
207Pb(stable)
Table I Emittance from 223Ra and daughters*.
Nuclide 223Ra 2l9Rn z1lPo z11pb 211Bi 207TI
a-Energy 5.64 MeV 6.75 MeV 7.39 MeV 6.55MeV
(3-Energy 0.47 MeV 0.47 MeV
(max)
Energy 0.207 0.248 0.271 0.017 0.24 S 0.017
Fraction.r
*Data from Seelmann-Eggebert et al., 1981 and Ekstrem et al., 1989
".Relative to the totai emitted energy for the complete decay chain.
The combined energy from the emitted radiation associated with the complete
decay
of 223 Ra and daughters: -27.5 MeV
Fraction of energy emitted as a-particles: 2: 96%
Fraction of energy emitted as 0-particles: 5 3%
Some gamma radiation (< 0,3 MeV total) is also e.mitted during decay and can
be
used to determine the quality and quantity of isotopes in samples using gamma
spectroscopy. E.g. radium-223 has a characteristic gamma peak at 154.19 keV
(5.59% abundance), radon-219 has a peak at 401.78 keV (6,6%) and bismuth-211
has
a 351.0 keV peak (12.8%) (Ekstrom et al., 1989). These can be used to
determine if
redistribution occurs for daughter isotopes in vivo. Also Z'3Ra has a 269.41
keV peak
CA 02358498 2001-07-03
WO 00140275 PCT/N099/00392
7
with 13.6% abundance, but this may be difficult to distinguish from a 271.23
keV
peak, with 9.9% abundance of 2"Rn.
Production methods has 'been described for Radium-223 (Atcher et al., 1989;
Howell
et al., 1997). 223Ra is a member of a natural radioactive family originating
from U(t1rz
= 7 x 108 y.) via "'Th (tin=25.6 y.) and the sequence "Th _+ Z"Pa (tlr2= 3.3 x
10'
y.) -~ 227 Ac (tlrz = 21.7 y.) __~ 227 Th (t,n =18.7 d.) -~, 2'3Ra (11.4 d.).
Atcher et al.
(1989) used a cation exchange system (Bio-rad AG 50) to produce 223Ra from
227Ac.
Howell et al. (1997) used the Z26Ra(n,y)227 Ra nuclear reaction to produce
223Ra. 227
Ra(t,n= 42 min) is rapidly transformed into 227 Ac (tla= 21.77 years) which
may be
separated by different methods from the 226Ra target material. Howell et al
(1997)
separated the'2'Ac chemically from a target solution. After that was 227Ac,
together
with its daughter products, transferred to an anion exchange column that
retained
227Th, while the mother and daughter of this nuclide was eluted. Ten days
later 223Ra
could be eluted from the ion exchange column. If clinical batches were to be
prepared
by use of the generator principle, the application of ion exchange columns
based on
an organic backbone may be suboptimal because radiolysis may prevent long term
multiple use of a radium generator based on this type of materials (Atcher et
al.,
1989).
Recently new materials have been developed, and are now commercial available,
that
are useful for separation of actinide radionuclides (selectivity for f-
elements versus
alkaline earth elements). These are based on silica particles covalently bound
to or
impregnated with active groups. Columns can be prepared using this material
allowing
the elution of some elements at conditions that can retain other elements. It
would
also be possible to use the active groups for the separation in wet/wet
extraction
systems using an organic and an aqueous phase.
CA 02358498 2001-07-03
WO 00/40275 PCr/N099/00392
8
EXAMPLES
In the following Example 1 223Ra was produced. The novel method according to
the
invention for producing u'Ra for biomedical uses comprises both columns of
inorganic matrix and liquid/liquid systems. A generator column containing a
methane
bis-phosphonic acid derivative on an inorganic matrix or the method can as
well
comprise a step of liquid/liquid extraction procedure in which one or more
P,P' di-
esterified methylene bis-phosphonic acid derivates are used as phase transfer
agents.
ln the method the generator column containing P,P' di-octyl methane bis-
phosphonic
acid on a silica matrix and the liquid/liquid extraction procedure is
performed using
P,P' di-octyl methylene bis-phosphonic acid or P,P' di(2-ethylhexyl) methane
bis-
phosphonic acid or combinations thereof as phase transfer agents. The
prosedure.with
respect to the generator column is performed by using mineral acids which
after
neutralization is capable of giving physiologically compatible solutions of
their salts,
preferably nitric acid or hydrochlorid acid. The concentration of said mineral
acids
being in the range of 0.01 to 8M, more preferably between 0.1 and 2M, most
preferably between 0.5 and IM. The liquid/liquid extraction step is performed
using a
water phase consisting of a mineral acid, preferably nitric acid or
hydrochloric acid,
the concentration of which being in the range of 0.01 to 8M, more preferably
between
0.1 and 2M most preferably between 0.8 and 1.5M.
EXAMPLE 1
ZZ'Ac and 227Th were isolated from a=31Pa source prepared 27 years earlier
(Sample
was provided by Radiochemistry Group, Department of Chemistry, University of
Oslo, Norway), by use of an f-element selective extraction chromatographic
resin.
The purified 227Ac and 277Th were subsequently adsorbed onto another f-element
selective extraction chromatographic resin and used as a cow for 223 Ra. The
latter
material has been used by Wu et al. (1997) for construction of a generator for
Z"Bi
based onZ2sAc.
Methods: A sample of the'3'Pa source (with daughters) in an aqueous solution
of 5
M HzS04and I M HF, was diluted 10 times with 1 M HCI. The solution was loaded
onto a column of 3 mm inner diameter and length of 70 mm containing TRU-resin
(EiChroM Industries, Darien, IL, USA), which had been pre-equilibrated with I
M
HCI.'3'Pa was retained on the column while 227Ac, 227 Th, and 223Ra was eluted
partly
by the loading procedure and partly by washing the column with additional 10
ml of
I M HC1. After this a 223Ra generatior was prepared by using a modification of
the
column packing technique described by Wu et al. (1997). A 3x50 mm column of
Siiica Actinide Resin (EiChroM, Darien, IL, USA) consisting of P,P' di-octyl
methane
bis-phosphonic acid (DIPEX, EiChroM Industries, Darien, IL, USA) on silica
particles with a diameter in the range of 20 - 50 m was prepared and
preconditioned
CA 02358498 2001-07-03
WO 00/40275 PCT/N099/00392
9
with 1M HCI. Approximately one half of the resin was then removed from the
column and mixed with the eluate from the TRU-resin column.
The eluate containing 217 Ac, n'Th and 223Ra was thereafter loaded onto 3 mm
i.d. and
50 mm long column containing Actinide-resin (Ac-resin) on 30-50 m silica
(EiCroM
Industries, Darien IL, USA). Briefly, the column had been prepared according
to the
method of Wu et al. (1997). After preconditioning the column with 1 M HCI,
half of
the material was removed and mixed with the eluate from the preceding step.
After 4 hours of gentle agitation at room temperature, the slurry containing
the
radionuclides was loaded onto the column. Finally, the column was washed with
5 nil
of I M HCI. The column was retaining 227 Ac and 227Th while 223Ra could be
eluted
with a few ml of either HCI or HNOa, without any significant breakthrough of
its
parent and grandparent radionuclides. If desired, a subsequent purification
step could
be added by simply eluting the 223 Ra eluate through a second AC-resin column
to
remove any traces of mother and grandmother nuclides.
The HCI solution containing the 22Ra could be diluted in a buffer, sterile
filtered and
used as such. Alternatively, the purified 223 Ra could be concentrated before
use by
loading the HCI solution onto a 2 mm i.d. and 25 mm long column containing a
resin,
e.g., AG SOW-X4-16 (Bio-Rad, Richmond, CA, USA). Thereafter the 223Ra could be
eluted nearly quantitatively by a small volume of 6 M HNO3. The HNO3 could
thereafter be evaporated of and the residue could be resolved in a solution
that could
subsequently be sterile filtered.
Radioactivity quality and quantity measurements were performed either using
Ge-detector (Canberra, Meriden, CT, USA) combined with an amplifier and bias
supply from EG&G Ortec (Oak Ridge, TN, USA) for gamma spectroscopy andlor a
Canberra (model 7404-0 1 A) combined with an EG&G Ortec for alpha
spectroscopy.
Results: In the TRU-resin column, 231Pa was quantitatively retained, i.e., the
breakthrough was less than the detection limit of 0.5 % compared to the
daughter
activity. Above 90% of the 227Ac and 227 Th was collected in the eluate from
the
TRU-resin. For the AC-resin, multiple experiments indicated typical yields of
60-85
kBq 223Ra per 100 kBq of n7 Th in the column (also named cow or generator) in
the
first few ml of stripping solution. The breakthrough of 227Ac and 227 Th was
determined to be less than (limited by detection capability) 4x10'3 % compared
to
223Ra. It should be noted that the described separation methods could also be
used
with the 227Ac produced from 226Ra via 226Ra (n, y)aZ7Ra -* 227Ac.
Conclusion: A set of methods is described for the production of 223 Ra
ensuring a
high yield and a high purity useful for biological applications. Its
distinction being the
greater facilitation of routine production of clinically relevant activity
levels of 223Ra
from 227Ac. This is performed using a generator column based on a silica
matrix (Wu
CA 02358498 2001-07-03
WO 00/40275 PGT/N099/00392
et al., 1997) as compared to previously presented procedures involving more
radiolytic sensitive ion-exchange resins containing organic matrixes (Atcher
et al.,
1989).
EXAMPLE 2
5 The biodistribution of radium-223 prepared as described in Example 1 was
studied.
Methods: Young male Balb/C mice with a body weight of 19-21 g were injected
with
9 kBq of'23Ra in 150 l of isotonic saline. Groups of five animals were
sacrificed and
dissected at 6 h and 3 days after injection. Sample weight was measured and
samples
were counted using (A) a "well type" Nal scintillation crystal (Harshaw Chemie
BV,
10 De Meern, Holland) combined with a Scaler Timer ST7 (NE Technology Ltd,
Reading, UK) digital unit, (B) a Beckman LS 6500 (Beckman Instruments Inc.
Fullerton, CA, USA). Relative abundances of radionuclides were studied in
blood,
liver, kidney, and in standard samples with mother/daughter in equilibrium,
using a
Ge-detector (Canbena, Meriden, CT, USA) combined with an amplifier and bias
supply from EG&G Ortec (Oak Ridge, TN, USA).
Results: The biodistribution data is presented in Table 2. The data shows that
223Ra
was selectively concentrated in bone compared to soft tissues. While all the
soft tissue
values were reduced between 6 h and 3 days after injection, the bone values
increased
with time. Femur to blood ratios increased from 129 to 691 from 6 h to 3 days.
Spleen had the highest retention measured among the soft tissues, but the
femur to
spleen ratio also increased with time from 6.4 to 23.7 between 6 h and 3 days
after
injection.
CA 02358498 2001-07-03
WO 00/40275 PCT/N099100392
11
Table 2 Biodistribution of radium-223 in Balb/C mice presented as % of
injected
dose per gram.
Tissue 6 hours 3 days
femur 25.86f 1.99 34.55t7.87
blood 0.20t0.23 0.05t0.10
kidney 4.04f0, 33 0.38 0.08
liver 0.893:0.18 0.22 0.32
lung 0.5910.56 0.06 0.07
muscle 0.720.39 0.30t0.16
heart 0.10t0.10 0.06 0.07
brain 0.0410.01 0.120.12
spleen 4.06f 1.4 1.460, 54
small intestine 0.790.26 0.04 0.03
large intestine 2.30f0.60 0.13t0.02
Based on gamma spectroscopy data no significant difference in relative
distribution of
radium-223 and its daughters, as determined by abundance of"'Bi, could be
observed
in the bone and most soft tissues. The ratio of 211Bi: 223Ra was in the spleen
at the 6
hour point on average 54% compared to a standard solution. In liver and
kidneys on
the other hand, the 211Bi :223Ra ratios in the samples were on the average 256
and 207
% of the standards respectively. This indicates that some translocation
occurred in the
soft tissues. Also the 211Bi activity in soft tissues was in general very low
compared to
bone activity of this nuclide. The "'Bi in the soft tissues may have been
generated
from n3Ra present in soft tissues.
Conclusion: Excellent bone to normal tissue radioactivity ratios were obtained
with
n3Ra and daughters, indicating a significant potential for the targeting of
calcified
tissues with this radionuclide series.
ExAmole 3
To examine if there was a difference in radioisotope retention between radium-
223
and bismuth-211 in bone samples, gamma spectroscopic data for bone versus a
standard solution with 22'Ra and daughter radionuclides in equilibrium was
studied.
Methods: Gamma spectroscopy with a germanium detector (Canberra, Meriden, CT,
USA) was performed on samples of femur from mice immediately after sacrificing
and
dissecting the animals. Samples of a standard solution of n3Ra and daughter
radionuclides in equilibrium were studied. The distinct gamma peaks at
CA 02358498 2001-07-03
WO 00/40275 = PC1'/N099/00392
12
351.0 keV (2l'Bi) and 154.2 keV (2=fRa) were used. A Localization Index (LI)
was
determined as follows:
LI = (Bs;lSei) / (Bx./SR,)
E.g., BB; - T"Bi count rate in bone; SR, - Z"Ra count rate in standard
Gamma spectra from five samples from the 6 h group and the 3 days group
respectively were compared, to five and three samples from the standard
solution
respectively, using Student t-test for data columns.
Results: The LI values were on average 0.85 (P=0.059) at the 6 h point and
0.97
(P=0.749) at the 3 day point. However, the differences were not significant
with
respect to the P=0.05 level for the data sets.
Conclusion: Even for the radionuclide representing the fourth transformation
in the
series from 223Ra, the 21 'Pb-transformation, the retention in bone was
similar to that
of 223Ra.
EXAMPLE 4
To study potential release of daughter isotopes after 223Ra was incorporated
in bone,
due to either nuclear recoil or diffusion processes, femurs from five animals
killed 6 h,
and 5 animals killed 3 days after injection were examined.
Methods: The bones were cleaved longitudinally, to expose the red marrow
(spongious) areas, and thereafter cut into small fragments of less than 3 mg.
Thereafter the samples were washed with Dulbeccos PBS (Sigma-Aldrich CO. LTD.,
Irvine, UK) using centrifugation. The supernatant was removed, mixed with
scintillation liquid (Insta-Gel 1 I plus, Packard BioScience BV, Groningen,
The
Netherlands) and counted on a scintillation counter (Beckman Instruments Inc.
Fullerton, CA, USA). After one day sample counting was repeated. A difference
in
counts after correcting for n3KA decay between the two measurements was used
as
indication of release of daughter nuclide(s) from bone matrix.
Results: Animals killed after 6 hours showed some release of activity from
bone.
Compared to the total activity in bone an average of 1.8% was dissolved in PBS
during washing. When the washing solutions were counted again after 12 h the
activity then were only on average 0.2% of the bone sample. This indicates
that some
translocation of daughter isotopes had occurred but to a very small degree
(probably
for less than 2% of daughter isotopes). Animals killed after 3 days showed no
significant counts compared to the background in the washing solution after
washing.
This indicates that if translocation occurred, it was below the detection
limit, which
was estimated to be less than 1% of the total bone radioactivity.
CA 02358498 2001-07-03
WO 00/40275 PGT/N099I00392
13
Conclusions: Based on the extractable radioactive fraction from finely
fragmented bone samples it is indicated that daughter nuclide release
(translocation)
from bone matrix is low for the radium-223 series.
EXAMPLE 5
It has been developed animal models with experimental metastasis pattern
resembling
those frequently observed in human patients (Engebraaten and Fodstad, 1999).
One of
these models consists of MT-1 cells injected intracardially into nude rats and
is
characterized by the consistent development of hind leg paralysis in the
animals.
Treatment (seven days after tumour cell inoculation) with the
chemotherapeutics
cisplatin or doxorubicin did not improve survival. Dissection and microscopic
examination of the spine from animals iffected by tumours revealed large
masses of
tumour cells replacing normal bone marrow and eroding the bony part of the
spine.
The skeletal involvement in the above developed model made it suitable to
demonstrate the therapeutic potential of 223Ra according to the invention
against
skeletal metastases.
Method: The therapeutic potential of radium-223 was studied in the MT-1/nude
rat
model where animals were inoculated with I x 106 MT-1 human breast cancer
cells by
injection into the left ventricle of the heart as described (Engebraaten and
Fodstad,
1999). These animals usually develop paralysis caused by growth of tumours in
the
spine. Groups of 4 and 5 animals each were then treated seven days later by
receiving
an intravenous injection of 200 l of a vehicle solution without or with 10
kBq of
radium-223 according to the invention.
Results: The group of four animals treated with vehicle solution alone
experienced
paralysis affected by tumour growth in the spine and was sacrificed between 20-
25
days (means 22,25 days) after tumour cell inoculation. In the group of five
animals
receiving vehicle solution containing Z'Ra one animal had paralysis after 26
days, one
,after 40 days and one after 64 days while the two remaining animals lived
throughout
the experimental follow-up period of 90 days after tumour cell inoculation,
without
showing signs of paralysis.
Conclusion: 223Ra demonstrated a significant anti-tumour effect in animals
with
skeletal metastases.
References.
Atcher RW, Friedman AM, Huizenga JR, Spencer RP. A radionuclide generator for
the production of 2"Pb and its daughter. J. Radioanal. Nucl. Chem. Letters
135,
215-221 (1989).
CA 02358498 2001-07-03
WO 00/40275 PCT/N099100392
14
Atkins HL, Mausner LF, Srivastava SC, Meinken GE, Cabahug GE, D'Alessandro
T. Tin-117m(4+)DTPA for palliation of pain from osseous metastases: A pilot
study.
J Nucl Med 36, 725 (1995).
Atkins HL. Overview of nucfides for bone palliation. App! Radiat Isot 49, 277-
283
(1998).
De Klerk, JNM, van Dijk, A., van het Schip, AD, Zonnenberg, BA, and van Rijk,
PP
Pharmacokinetics of Rhenium- 186 after administration of rhenium- 186- HEDP to
patients with bone metastases. JNuc! Med 33, 646-651 (1992).
Delikan O. Preparation of 224 Ra for therapy of ankylosing spondylitis. Health
Phys
35, 21-24 (1978).
Ekstrom L, Spanier R. The EN SDF radioactivity data base for 1BM-PC and
computer network Access. Dept. Of Physics, University of Lund, Sweden (1989).
Engebraaten, O. and Fodstad, O. Site specific experimental metastasis patterns
of two
human breast cancer cell lines in nude rats. Int..I Cancer 82 (2), 219-225
(1999)
Feinendegen LE, McClure JJ. Meeting Report. a-emitters for medical therapy -
Workshop of the United States Department of Energy. Denver, Colorado, May
3 0-31, 1996, Radial. Res. 148, 195 (1997).
Foss6 SD, Paus E, LochoffM, Melbye R, Backe S, and Aas M. 89strontium in bone
metastases from hormone resistant prostate cancer: Palliation effect and
biochemical
changes. Br J Cancer, 66, 177-180 (1992).
Garret R. Bone destruction in cancer. Semin Oncol 72, 3433-343 5 (1993).
Hall EJ. Radiology for the radiologist. Fourth edition, JB Lippincott Co.
Philadelphia,
s. 15 3 -164 (1994).
= Hassfjell SP, Hoff P, Bruland fr3S, Alstad J. 2i2Pb/212Bi-EDTMP-Synthesis
and
biodistribution of a novel bone seeking alpha-eniitting radiopharmaceutical. J
Labelled Compds Radiopharm 34, 717-734 (1994).
Hassfjell, SP, Bruland, 0S, Hoff, P. 2"Bi-DOTMP- An alpha particle emitting
bone
seeking agent for targeted radiotherapy. Nuci Med Biol 24, 23 1-23 7 (1997).
Howell RW, Goddu SM, Narra VR, Fisher DR, Schenter RE, Rao DV. Radiotoxicity
of Gadolinium- 148 and radium-223 in mouse testes. Relative biological
effectiveness
of alpha-particle emitters in vivo. Radial Res 147, 342-348 (1997).
Kanis JA. Bone and cancer. Pathophysiology and treatment of inetastases. Bone
17,
101 s- 1053 (1995).
CA 02358498 2001-07-03
WO 00/40275 PC'P/N099/00392
Larsen RH, Murud KM, Akabani G, Hoff P, Bruland 0S, Zalutsky NIR ."'At- and
13'I-labeled bisphosphonates with high in vivo stability and bone
accumulation. JNucl
Med 40, 1197 - 1203 (1999).
Lee CK, Aeppli DM, Unger J, Boudreau RJ, Levitt SH. Strontium-89 chloride
5 (Metastron) for palliative treatment of bony metastases: The University of
Minnesota
experience. Am J Clin Oncol 19, 102-107 (1996).
Lloyd RD, Bruenger FW, Rn:Ra ratios in bone of beagles injected with 226Ra.
Health
Phys. 60, 567-568 (1991).
Lloyd RD, Mays CW, Taylor GN, Atherton DK Bruenger FW, Jones CW.
10 Radium-224 retention, distribution, and dosimetry in beagles. Radial Res
92, 280-295
(1982).
Muggenburg BA, Hahn, FF, Griffith Jr WC, Lloyd RD, Boecker BB. The biological
effects of radium-224 injected into dogs. Radtat Res 146, 171-186 (1996).
Miiller WA. Studies on short-lived internal a-emitters in mice and rats Part
I. 2Z0Ra.
15 Int J Radiat Biol 20, 27-3 8(1971).
Nielsen, OS, Munro AJ, Tannock IF. Bone metastases: Pathophysiology and
management policy. J Clin Oncol 9, 509-524 (1991).
Raabe OG, Parks NJ. Skeletal uptake and lifetime retention of Sr-90 and Ra-226
in
beagles. Radial Res 133, 204-218 (1993).
Ritter MA, Cleaver JE, Tobias CA. High-LET radiations induce a large
proportion of
nonrejoining DNA breaks. Nature, 266, 653-655 (1977).
Rundo J. The biological behaviour of 224Ra (ThX) and its daughters. Health
Phys
35, 13-20 (1978).
Seelmann-Eggebert W, Pfennig G, Munzel H; Klewe-NebeniusH. Nuklidkarte,
Kernforschungszentrum Karlsruhe (1981).
Silberstein EB. Editorial : Dosage and response in radiopharmaceutical therapy
of
painful osseous metastases..l. Nucl. Med., 37, 249-252 (1996).
Wu C, Brechbiel MW, Gansow OA. An improved production of 213 Bi from 221Ac.
Radiochimica Acta 79, 141-145 (1997).
